thiazolyl blue has been researched along with Lymphoma, Non-Hodgkin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, F; Joshi, I; Obasaju, C; Smith, MR | 1 |
| Efferth, T; Fabry, U; Glatte, P; Osieka, R | 1 |
2 other study(ies) available for thiazolyl blue and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Combined Modality Therapy; Deoxycytidine; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Rituximab; Tetrazolium Salts; Thiazoles; Translocation, Genetic | 2005 |
Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.
Topics: Apoptosis; Caffeine; Carboplatin; Cluster Analysis; Coloring Agents; Daunorubicin; Drug Resistance, Neoplasm; Flow Cytometry; G2 Phase; Gamma Rays; Gene Expression Regulation, Leukemic; Glutathione; GTP-Binding Proteins; HL-60 Cells; Humans; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Multivariate Analysis; Oncogene Proteins v-fos; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; ras Proteins; S Phase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1995 |